- |||||||||| paclitaxel / Generic mfg.
Journal: Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach. (Pubmed Central) - Feb 7, 2025
The uniform size and high drug loading capacity of A@HAP NPs facilitated their accumulation within tumors through enhanced permeability and retention effect as well as HA-mediated targeting, providing a solid foundation for subsequent synergistic therapy and immunoregulation. In vitro and in vivo studies demonstrated that A@HAP NPs exhibited potent cytotoxicity against tumor cells while also remodeling the immune-suppressive tumor microenvironment by promoting antigen presentation and inducing dendritic cell maturation, thus offering a novel approach for colorectal cancer chemoimmunotherapy.
- |||||||||| Review, Journal, Cancer stem, IO biomarker: The missing link between cancer stem cells and immunotherapy. (Pubmed Central) - Nov 14, 2024
We discuss how these methods can aid in recognizing CSCs in several cancer types, comprising brain, breast, liver, stomach, and colon cancer. Furthermore, we explore different immunotherapeutic strategies targeting CSCs, including stimulating cancer-specific T cells, modifying immunosuppressive TMEs, and antibody-mediated therapy targeting CSC markers.
- |||||||||| Cross-Linking of Erythrocyte CD44 Promotes Plasmodium Falciparum Invasion (Room 28 A-D (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2406;
Together, our findings support a model where CD44 cross-linking promotes invasion by altering the RBC membrane, including increasing basigin accessibility and facilitating signaling to the RBC cytoskeleton, potentially via EBA-175. These studies on the role of RBC CD44 advance new insights into the mechanisms underlying P. falciparum invasion, with the potential to inform new therapeutic approaches to combat malaria.
- |||||||||| Preclinical, Journal: Validation and in vivo characterization of research antibodies for Moesin, CD44, Midkine, and sFRP-1. (Pubmed Central) - Oct 24, 2024
sFRP-1 protein expression was 11.9 times greater in 5xFAD compared to WT. These data confirm the utility of these selective commercially available antibodies against Moesin, CD44, Midkine, and sFRP-1 for in vivo studies in mice and provide insight into the use of 5XFAD mice for in vivo target engagement studies for these target proteins.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal, IO biomarker: Alternative splicing in ovarian cancer. (Pubmed Central) - Oct 19, 2024
In clinical settings, bevacizumab, a humanized monoclonal antibody that specifically targets the VEGF-A isoform, has demonstrated beneficial effects in the treatment of patients with advanced epithelial ovarian cancer. In conclusion, this review constitutes the first comprehensive and detailed exposition of the intricate interplay between alternative splicing and ovarian cancer, underscoring the significance of alternative splicing events as pivotal determinants in cancer biology and as promising avenues for future diagnostic and therapeutic intervention.
- |||||||||| Inhibiting STAT3-Mediated Glutathione Metabolism Attenuates Parietal Epithelial Cell Activation in Proliferative Glomerulopathy (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4206;
In conclusion, this review constitutes the first comprehensive and detailed exposition of the intricate interplay between alternative splicing and ovarian cancer, underscoring the significance of alternative splicing events as pivotal determinants in cancer biology and as promising avenues for future diagnostic and therapeutic intervention. These data suggest that inhibition of GSH metabolism might be a key target in attenuating PEC activation, proliferation, and crescent formation in proliferative glomerulopathy.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Dual-Prodrug-Based Hyaluronic Acid Nanoplatform Provides Cascade-Boosted Drug Delivery for Oxidative Stress-Enhanced Chemotherapy. (Pubmed Central) - Sep 11, 2024
Hence, we constructed a dual NO prodrug (alkynyl-JSK) and doxorubicin prodrug (cis-DOX)-conjugated HA nanoparticle (HA-DOX-JSK NPs), which achieved cascade-boosted drug delivery efficiency based on a relay strategy of NO-mediated deep tumor penetration?HA target CD44 tumor cell uptake?tumor microenvironment (TME)-responsive drug release...Based on this strategy, the tumor inhibition rate in breast cancer was up to 87.8% in vivo. The relay drug-delivery HA system would greatly cascade-boost drug accumulation in deep tumors for efficient solid tumor therapy.
- |||||||||| Journal: Multiplexed immunolabelling of cancer using bioconjugated plasmonic gold-silver alloy nanoparticles. (Pubmed Central) - Aug 22, 2024
With this coating and using the classical EDC/sulfo-NHS cross-linking procedure, we also demonstrate the successful multiplexed immunolabelling of Her2, CD44, and EpCAM in breast cancer cell lines (SK-BR-3 and MDA-MB-231). Furthermore, we introduce a user-friendly software for automatic NP detection and classification by colour, providing a promising proof-of-concept for the practical application of immunoplasmonic techniques in the quantitative analysis of biopsies in the clinical setting.
- |||||||||| Photoimmunotherapy of prostate cancer (Hall B / Level 0) - Jul 26, 2024 - Abstract #DGU2024DGU_1139;
This study provides an in vitro proof-of-concept for a future strategy to selectively destroy light-accessible superficial CD44-expressing TNBC tumors and their metastatic lesions which are inaccessible to therapeutic light. PIT with our new dye WB692-CB2 has the potential to be used in the future for the intraoperative elimination of residual tumor cells in prostate carcinoma.
- |||||||||| 5-fluorouracil / Generic mfg., methotrexate / Generic mfg.
Journal: Hyaluronic acid-conjugated methotrexate and 5-fluorouracil for targeted drug delivery. (Pubmed Central) - Jul 6, 2024
By using drugs to act on patient-derived colorectal, liver, and breast cancer organoids, the anticancer effect of the nanodrug was identified and verified. These results showed that the nanodrug system developed in this study may have great potential as a targeted therapy for cancer.
- |||||||||| Journal: Unveiling the Power of Cloaking Metal-Organic Framework Platforms via Supramolecular Antibody Conjugation. (Pubmed Central) - Jun 7, 2024
The therapeutic effectiveness of the antibody-conjugated MOF (anti-M808) was further evaluated through in vivo imaging and the assessment of tumor inhibition effects using IR-780-loaded EGFR-M808 in a 4T1 tumor xenograft model employing nude mice. This study therefore provides insight into the use of supramolecular antibody conjugation as a promising method for developing MOF-based drug delivery systems.
- |||||||||| Review, Journal, Cancer stem, IO biomarker: Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways. (Pubmed Central) - Apr 17, 2024
We aim to provide insights into the potential of these therapies to revolutionize cancer treatment, underscoring the critical need for a multi-faceted approach in the battle against cancer. This comprehensive analysis demonstrates how advances made in the CSC field have informed significant developments in novel targeted therapeutic approaches, with the ultimate goal of achieving more effective and durable responses in cancer patients.
- |||||||||| miransertib (MK-7075) / Merck (MSD), Gilotrif (afatinib) / Boehringer Ingelheim
Journal: The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells. (Pubmed Central) - Mar 28, 2024
Of various human epidermal growth factor receptor (HER) inhibitors, only the anti-HER2 monoclonal antibody (mAb) Herceptin/trastuzumab and the antibody-drug conjugate trastuzumab deruxtecan (T-Dxd) has been approved for the treatment of patients with stomach cancer...Of various HER inhibitors, the irreversible pan-HER family inhibitors (e.g., afatinib) were more effective than the reversible dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor (TKI) lapatinib and the EGFR-specific TKI erlotinib in inhibiting the growth of HSCCLs. Of agents targeting different downstream cell signaling molecules, dasatinib targeting Ab1/Src/C-Kit, trametinib targeting MERK1/2 and miransertib targeting AKT1/2/3 inhibited growth of majority of HSCCLs, with the IC50 values ranging from 2 nM to 7
- |||||||||| metformin / Generic mfg.
Journal: Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform. (Pubmed Central) - Mar 26, 2024
The study preliminarily revealed anti-ENO1 antibody combined with metformin could overcome drug resistance against CSCs by inhibiting the Wnt//?-catenin pathway and might serve as a potential precursor platform for screening ADC. More importantly, it is reasonably believed that antibody-based drug combination therapy might function as an encouraging tool for oncotherapy.
- |||||||||| lixudebart (ALE.F02) / Alentis Therap
Novel therapeutic for crescentic glomerulonephritis through targeting CLDN1 in parietal epithelial cells (A5) - Mar 23, 2024 - Abstract #ERAEDTA2024ERA_EDTA_2444;
P2
Lixudebart (formerly ALE.F02) is a first-in-class monoclonal antibody that specifically targets and blocks exposed CLDN1 in injured epithelial cells... Our results suggest a functional role of CLDN1 in the pathogenesis of CrGN, providing preclinical proof-of-concept for anti-CLDN1 antibodies as a novel therapeutic approach in patients with CrGN.
- |||||||||| Journal: Vitamin C, lactoferrin and elastin-Advancing the science. (Pubmed Central) - Feb 26, 2024
From this current study, the combination of SAC with lactoferrin may be responsible for this additive stimulatory effect on elastin. This presents a significant advance in topical antioxidant formulations where the Vitamin C component provides antioxidant and collagen stimulation with additional elastin stimulation rather than degradation.
- |||||||||| Review, Journal, IO biomarker, Immune cell: Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs. (Pubmed Central) - Jan 23, 2024
To date, many therapies targeting CSCs have been evaluated, including monoclonal antibodies, antibody?drug conjugates, bispecific antibodies, tumor vaccines adoptive cell therapy, and small molecule inhibitors. With the development of CSC-/niche-targeting technology, as well as the integration of multidisciplinary studies, novel therapies that eliminate CSCs and reverse their immunosuppressive microenvironment are expected to be developed for the treatment of solid tumors, including colorectal cancer.
- |||||||||| Journal, IO biomarker, Stroma: Comprehensive cell surface protein profiling of human mesenchymal stromal cells from peritoneal dialysis effluent and comparison with those from human bone marrow and adipose tissue. (Pubmed Central) - Aug 21, 2023
The BM-MSCs but not both AT-MSCs and pMSCs express cytokine receptors (IFN?R, TNFI/IIR, IL-1R, IL-4R, IL-6R, and IL-7R). In conclusion, pMSCs exhibited a typical cell surface phenotype of MSCs, which was not the same as on BM-MSCs or AT-MSCs, suggesting that the pMSCs may represent a different MSC lineage from peritoneal cavity.
- |||||||||| Review, Journal, BRCA Biomarker, PARP Biomarker, IO biomarker: Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. (Pubmed Central) - Aug 4, 2023
This review sheds light on various targeting strategies, including cellular and molecular targets, signaling pathways, poly (ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and immune checkpoint inhibitors PARP, immunotherapy, ADCs have all found a place in the current TNBC therapeutic paradigm. The role of photothermal therapy (PTT) and photodynamic therapy (PDT) has also been explored briefly.
- |||||||||| Journal, Circulating tumor cells, Tumor cell: Chemically-Modified Sepharose 6B Beads for Collection of Circulating Tumor Cells. (Pubmed Central) - Aug 2, 2023
These beads, when mixed with MDAMB231 and Jurkat cells and filtered through a 40 ?m filter, can capture ~80% of MDAMB231 cells. Furthermore, the antibody-modified Sepharose 6B can be stored at four degrees Celsius for a period exceeding six months.
- |||||||||| imatinib / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
Journal: Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals. (Pubmed Central) - Nov 18, 2022
Inhibition of focal adhesion kinase (FAK), activation of multiple stress responsible signal proteins such as c-JunN-terminal kinase (JNK) and mitogen-activated protein kinase p38 (p38MAPK), and expression of SMAD4, as well as activation of caspase-3 were obviously observed in the tumor cells, suggesting that h4147D induced tumor shrinkage by inducing multiple stress responsible signals. These results suggest that the anti-CD147 antibody h4147D offers promise as a new antibody drug candidate.
- |||||||||| paclitaxel / Generic mfg.
Journal: Combination of polythyleneimine regulating autophagy prodrug and Mdr1 siRNA for tumor multidrug resistance. (Pubmed Central) - Nov 15, 2022
Here, small interfere RNA (siRNA) is incorporated into polymer-drug conjugates (PEI-PTX, PP) which are composed of polyethyleneimine (PEI) and paclitaxel (PTX) via covalent bonds, and hyaluronic acid (HA) is coated on the surface of PP/siRNA to achieve long blood cycle and CD44-targeted delivery...Both in vitro and in vivo studies confirm that the nanoassemblies can successfully deliver PTX and siRNA into tumor cells and significantly inhibited A549/T tumor growth. In summary, the polymeric nanoassemblies provide a potential strategy for combating both pump and non-pump resistance via the synergism of RNAi and autophagy modulation.
- |||||||||| Molecular Determinants of Human Red Blood Cell Survival in Murine Circulation (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3939;
In summary, the polymeric nanoassemblies provide a potential strategy for combating both pump and non-pump resistance via the synergism of RNAi and autophagy modulation. Our data show that CD47 and CD59 expression on human RBCs increases their survival after transfusion, and suggest that pre-transfusion profiling of CD47 and CD59 molecules could help predict the efficiency of human RBC transfusion.
- |||||||||| OTS167 / OncoTherapy
Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1570;
MELK inhibitor (MELKi) OTS167 is in clinical trials but it lacks specificity and cross-reacts with other essential kinases...We performed a cytokine antibody array and are validating the top targets. Further, we will evaluate 30e in combination with standard-of-care treatment for toxicity and inhibition of metastasis.
|
